Abstract
Immunotherapy via PD-1/PD-L1 blockade is a promising strategy to eradicate cancer cells. However, the PD-L1 pathological level is inconsistent with the therapeutic response and is not a reliable biomarker to stratify patients for anti-PD-1/PD-L1 therapy. Here, we describe patient sample deglycosylation in an immunohistochemistry (IHC) assay to resolve this challenge. This protocol facilitates antigen retrieval by removing N-glycans from surface antigens on formalin-fixed paraffin-embedded (FFPE) tissue slides and can be applied in medical pathology for multiple cancer types. For complete details on the use and execution of this profile, please refer to Lee et al. (2019).
Original language | English (US) |
---|---|
Article number | 101198 |
Journal | STAR Protocols |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - Mar 18 2022 |
Keywords
- Antibody
- Cancer
- Health Sciences
- Immunology
- Microscopy
- Molecular Biology
- linical Protocol
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
- General Neuroscience
- General Immunology and Microbiology
- General Medicine
MD Anderson CCSG core facilities
- Tissue Biospecimen and Pathology Resource
- Functional Genomics Core